HOME › DRUGS › DASATINIB (ANHYDROUS)
ACTIVE SUBSTANCE / INN

DASATINIB (ANHYDROUS)

Brand name(s): Sprycel, Dasatinib Accordpharma, Dasatinib Accord
EMA LISTED
WITHDRAWN
AUTHORISED
Precursor Cell Lymphoblastic Leukemia-Lymphoma;Leukemia, Mye…
ACTIVE SUBSTANCE
Dasatinib (Anhydrous)
REGULATORS
EMA
SPONSORS / MAH
Bristol-Myers Squibb Pharma EEIG, Accord Healthcare S.L.U.
TOTAL APPLICATIONS
3
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
SprycelBristol-Myers Squibb Pharma EEIGAuthorised20/11/2006Precursor Cell Lymphoblastic Leukemia-Lymphoma;Leukemia, Myelogenous, Chronic, B…
Dasatinib AccordAccord Healthcare S.L.U.Withdrawn24/03/2022Precursor Cell Lymphoblastic Leukemia-Lymphoma;Leukemia, Myelogenous, Chronic, B…
Dasatinib AccordpharmaAccord Healthcare S.L.U.Withdrawn24/03/2022Precursor Cell Lymphoblastic Leukemia-Lymphoma;Leukemia, Myelogenous, Chronic, B…

FULL INTELLIGENCE ON DASATINIB (ANHYDROUS)

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →